# One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

> **NCT00142337** · PHASE2 · COMPLETED · sponsor: **Institut de Recherche pour le Developpement** · enrollment: 244 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Zidovudine (ZDV)
- **DRUG:** Didanosine (ddI)

## Key facts

- **NCT ID:** NCT00142337
- **Lead sponsor:** Institut de Recherche pour le Developpement
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-05
- **Final completion:** 2009-02
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2012-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142337, "One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00142337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*